<p>Evercore ISI 分析师 Gavin Clark-Gartner 维持了对 MIRM 股票的看涨态度，今天给予了买入评级。</p>
<h3>TipRanks 网络星期一促销</h3>
<ul>
<li>申请 TipRanks Premium 享受 60% 的折扣，获取数据支持的洞察和研究工具，让您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
<p>Gavin Clark-Gartner 给予买入评级是基于与 Mirum Pharmaceuticals 战略收购和市场潜力相关的多种因素。收购 Bluejay Tx 被视为一个非常有利的举措，具有显著的临床和监管成功潜力。该交易的结构具有较高的成功概率，预计的商业协同效应表明，Mirum Pharmaceuticals 只需实现适度的峰值销售即可实现盈亏平衡。</p>
<p>此外，支持收购的临床数据非常强劲，具有合理的作用机制和良好的二期结果。即将进行的三期研究预计成功概率很高，特别是与现有治疗方法相比。HDV 指标的市场规模相当可观，Mirum Pharmaceuticals 预计在美国和国际市场上都将实现显著的峰值销售。这些因素为公司的股票前景提供了积极的展望，证明了买入评级和每股 94 美元的更新目标价的合理性。</p>
<p>根据 TipRanks，Clark-Gartner 是一位五星级分析师，平均回报率为 27.4%，成功率为 68.57%。Clark-Gartner 关注医疗保健行业，专注于 AbbVie、Vera Therapeutics 和 Insmed 等股票。</p>
<p>在今天发布的另一份报告中，Cantor Fitzgerald 也维持了该股票的买入评级，目标价为 130.00 美元。</p>

MIRM

<p>Evercore ISI 分析师 Gavin Clark-Gartner 维持对 Mirum Pharmaceuticals 的 “买入” 评级，原因在于其战略收购和市场潜力。收购 Bluejay Tx 是有利的，拥有强劲的临床数据和预期的商业协同效应。Mirum 预计 HDV 指标的峰值销售额将显著。Clark-Gartner 是一位五星级分析师，设定的目标价为每股 94 美元。Cantor Fitzgerald 也维持 “买入” 评级，目标价为 130 美元</p>

<p>Evercore ISI analyst Gavin Clark-Gartner has maintained their bullish stance on MIRM stock, giving a Buy rating today.</p>
<div class="lb-trans"><p>Evercore ISI 分析师 Gavin Clark-Gartner 维持了对 MIRM 股票的看涨态度，今天给予了买入评级。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 网络星期一促销</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>申请 TipRanks Premium 享受 60% 的折扣，获取数据支持的洞察和研究工具，让您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
</div><p>Gavin Clark-Gartner has given his Buy rating due to a combination of factors related to Mirum Pharmaceuticals’ strategic acquisition and promising market potential. The acquisition of Bluejay Tx is seen as a highly favorable move, with the potential for significant clinical and regulatory success. The deal is structured with a strong probability of success, and the expected commercial synergies suggest that Mirum Pharmaceuticals would only need to achieve a modest level of peak sales to break even.</p>
<div class="lb-trans"><p>Gavin Clark-Gartner 给予买入评级是基于与 Mirum Pharmaceuticals 战略收购和市场潜力相关的多种因素。收购 Bluejay Tx 被视为一个非常有利的举措，具有显著的临床和监管成功潜力。该交易的结构具有较高的成功概率，预计的商业协同效应表明，Mirum Pharmaceuticals 只需实现适度的峰值销售即可实现盈亏平衡。</p>
</div><p>Moreover, the clinical data supporting the acquisition is robust, with a logical mechanism of action and strong Phase 2 results. The upcoming Phase 3 studies are anticipated to have a high probability of success, particularly in comparison to existing treatments. The market size for the HDV indication is substantial, with Mirum Pharmaceuticals projecting significant peak sales both in the U.S. and internationally. These factors contribute to a positive outlook for the company’s stock, justifying the Buy rating and the updated price target of $94 per share.</p>
<div class="lb-trans"><p>此外，支持收购的临床数据非常强劲，具有合理的作用机制和良好的二期结果。即将进行的三期研究预计成功概率很高，特别是与现有治疗方法相比。HDV 指标的市场规模相当可观，Mirum Pharmaceuticals 预计在美国和国际市场上都将实现显著的峰值销售。这些因素为公司的股票前景提供了积极的展望，证明了买入评级和每股 94 美元的更新目标价的合理性。</p>
</div><p>According to TipRanks, Clark-Gartner is a 5-star analyst with an average return of 27.4% and a 68.57% success rate. Clark-Gartner covers the Healthcare sector, focusing on stocks such as AbbVie, Vera Therapeutics, and Insmed.</p>
<div class="lb-trans"><p>根据 TipRanks，Clark-Gartner 是一位五星级分析师，平均回报率为 27.4%，成功率为 68.57%。Clark-Gartner 关注医疗保健行业，专注于 AbbVie、Vera Therapeutics 和 Insmed 等股票。</p>
</div><p>In another report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $130.00 price target.</p>
<div class="lb-trans"><p>在今天发布的另一份报告中，Cantor Fitzgerald 也维持了该股票的买入评级，目标价为 130.00 美元。</p>
</div>

Strategic Acquisition and Market Potential Drive Buy Rating for Mirum Pharmaceuticals

- Evercore ISI 分析师 Gavin Clark-Gartner 维持对 MIRM 股票的买入评级。  
- 该评级基于 Mirum Pharmaceuticals 的战略收购及市场潜力。  
- 收购 Bluejay Tx 被视为有利举措，预计将带来显著的临床和监管成功。  

战略性收购和市场潜力推动了对 Mirum Pharmaceuticals 的买入评级